Vir Biotechnology, Inc. Operating Lease, Liability, Noncurrent
Vir Biotechnology, Inc. (VIR) had Operating Lease, Liability, Noncurrent of $84.14 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability, Noncurrent $84.14M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $86.64M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $89.05M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $91.22M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $84.14M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $86.64M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $89.05M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $91.22M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $93.41M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $88.17M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $90.14M 10-K · filed 2026-02-23 |
| 2024-09-30 | $93.41M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $95.02M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $109.17M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $111.67M 10-K · filed 2025-02-27 |
| 2023-09-30 | $114.12M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $117.81M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $121.46M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $123.84M 10-K · filed 2024-02-26 |
| 2022-09-30 | $126.94M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $130.21M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $132.81M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $133.56M 10-K · filed 2023-02-28 |
| 2021-09-30 | $68.60M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $68.94M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $66.61M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $66.56M 10-K · filed 2022-02-28 |
| 2020-09-30 | $12.09M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $12.76M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $13.53M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |